Chemical Component Summary

NameIBANDRONATE
Identifiers[1-hydroxy-3-(methyl-pentyl-amino)-1-phosphono-propyl]phosphonic acid
FormulaC9 H23 N O7 P2
Molecular Weight319.23
TypeNON-POLYMER
Isomeric SMILESCCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
InChIInChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKeyMPBVHIBUJCELCL-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count42
Chiral Atom Count1
Chiral AtomsN22
Bond Count41
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00710 Different stereochemistry
NameIbandronate
Groups
  • approved
  • investigational
DescriptionIbandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Synonyms
  • Bondronat
  • Ibandronic Acid
SaltsIbandronate sodium
Brand Names
  • Bondronat
  • Boniva
  • Ibandronate Sodium
  • ADRONiL
  • Bonviva
Affected OrganismHumans and other mammals
IndicationFor the treatment and prevention of osteoporosis in postmenopausal women.
PharmacologyIbandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
Mechanism of actionThe action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Route of administration
  • Intravenous
  • Oral
Categories
  • Bone Density Conservation Agents
  • Bone Resorption
  • Chemical Actions and Uses
  • Diphosphonates
  • Drugs Affecting Bone Structure and Mineralization
ATC-CodeM05BA06
AHFS-Code92:00
CAS number114084-78-5

Drug Targets

NameSequence SearchPharmacological ActionActions
Farnesyl pyrophosphate synthaseMPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCW...yesinhibitor
yesantagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682